Why Biogen's Recent Rebound May Not Last -- at Least for Now

Multinational biotech Biogen (NASDAQ: BIIB) is facing two important decisions -- one that could open the door to a vast new market (Alzheimer's disease treatment) and another that could challenge the dominance of its top-selling multiple sclerosis (MS) drug. It's the perfect moment to keep an eye on the share price, but with those two unknowns hovering, it may be too early for biotech investors to expect steady gains or a lasting rebound.